ArticleAnnals of clinical and translational neurology2014
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
Article in Annals of clinical and translational neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Vitamin D supplementation has no effects on progression of motor dysfunction in amyotrophic lateral sclerosis (ALS).European journal of clinical nutrition · 2020Trial
- Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE).Neurology(R) neuroimmunology & neuroinflammation · 2019Trial
- Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials.Journal of neurology · 2018Trial
- Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up.PloS one · 2016Trial
- Changes in the Expression of TGF-Beta Regulatory Pathway Genes Induced by Vitamin D in Patients with Relapsing-Remitting Multiple Sclerosis.International journal of molecular sciences · 2023Article
- Association between vitamin D deficiency and multiple sclerosis- MRI significance: A scoping review.Heliyon · 2023Article
- Extracellular Vesicles as Pro- and Anti-inflammatory Mediators, Biomarkers and Potential Therapeutic Agents in Multiple Sclerosis.Aging and disease · 2021Review
- Vitamin D and SARS-CoV-2 infection-evolution of evidence supporting clinical practice and policy development : A position statement from the Covit-D Consortium.Irish journal of medical science · 2021Article
- Obesity in Pediatric-Onset Multiple Sclerosis: A French Cohort Study.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Reply to Jakovac: COVID-19, vitamin D, and type I interferon.American journal of physiology. Endocrinology and metabolism · 2020Article
- Review
- Vitamin D enhances responses to interferon-β in MS.Neurology(R) neuroimmunology & neuroinflammation · 2019Article
- Lifestyle and Environmental Factors in Multiple Sclerosis.Cold Spring Harbor perspectives in medicine · 2019Review
- Vitamin D and Multiple Sclerosis: A Comprehensive Review.Neurology and therapy · 2018Review
- VDR and CYP24A1 Expression Analysis in Iranian Relapsing-Remitting Multiple Sclerosis Patients.Cell journal · 2017Article
- Association of vitamin D status and clinical and radiological outcomes in a treated MS population in Poland.Brain and behavior · 2017Article
- Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis.Nature reviews. Neurology · 2017Review
- Do vitamin D levels affect antibody titers produced in response to HPV vaccine?Human vaccines & immunotherapeutics · 2015Article
- The Association of Vitamin D Receptor Polymorphisms with Multiple Sclerosis in a Case-Control Study from Kuwait.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 10 institutions in 8 countries.
Funding
Abstract
objectiveSome previous studies suggest modest to strong effects of 25-hydroxyvitamin D (25(OH)D) on multiple sclerosis (MS) activity. The objective of this study was to explore the mechanistic rationale that may explain potential clinical effects of 25(OH)D.
methodsThis study measured serum 25(OH)D levels and global gene expression profiles over a course of up to 2 years in patients starting treatment with interferon beta-1b (IFNB-1b) after a clinically isolated syndrome. MS disease activity was assessed by the number of gadolinium-enhancing lesions present on repeated magnetic resonance imaging (MRIs).
resultsThe number of gadolinium-enhancing lesions was highly significantly associated with 25(OH)D levels. Conducting various systems-level analyses on the molecular level, multiple lines of evidence indicated that 25(OH)D regulates expression dynamics of a large gene-gene interaction system which primarily regulates immune modulatory processes modulating MS activity. The vitamin D response element was significantly enriched in this system, indicating a direct regulation of this gene interaction network through the vitamin D receptor. With increasing 25(OH)D levels, resulting regulation of this system was associated with a decrease in MS activity. Within the complex network of genes that are regulated by 25(OH)D, well-described targets of IFNB-1b and a regulator of sphingosine-1-phosphate bioavailability were found. The 25(OH)D effects on MS activity were additively enhanced by IFNB-1b.
interpretationHere, we provide mechanistic evidence that an unbalanced 25(OH)D gene expression system may affect MS activity. Our findings support a potential benefit of monitoring and managing vitamin D levels (e.g., through supplementation) in early MS patients treated with IFN-beta-1b.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.